Senior Director, Immunology and Translation

CSL Behring is a global biopharmaceutical leader committed to developing innovative therapies for patients with rare and serious diseases. Our Immunology franchise is advancing a diverse pipeline targeting autoimmune and inflammatory conditions across rheumatology, neuroimmunology, and rare dermatology.

Could you be our next Senior Director, Immunology and Translation? The job is in our Waltham MA or Melbourne Australia Office. This is a hybrid position and is onsite three days a week. You will report to the Research Therapeutic Area Lead, Immunology/Transplant and Vaccines.

You will serve as the internal subject matter authority on immunology disease biology, therapeutic target identification, and contribute to the research therapeutic strategy. You will bring end-to-end experience from early ideation through first-in-disease and will partner closely with cross-functional teams including discovery research, translational medicine, clinical development, and business development to shape and advance CSL Behring's immunology pipeline.

This role is critical to CSL Behring's ambition to build a best-in-class immunology franchise and will directly influence portfolio prioritization, target assessment, and early clinical program design.

RESPONSIBILITIES:

Scientific Leadership & Disease Area Expertise

• Serve as the primary scientific expert and internal champion for one or more immunology disease areas, including but not limited to rheumatology, neuroimmunology, and rare dermatology

• Translate deep mechanistic understanding of immune pathology into actionable therapeutic hypotheses and target identification strategies

• Maintain a current and comprehensive view of the competitive landscape, emerging science, and unmet medical need across assigned disease areas

• Represent CSL Behring at key scientific conferences, advisory boards, and KOL meetings; build and leverage a broad external network of thought leaders, clinical investigators, and academic collaborators

Pipeline Development & Asset Progression

• Drive end-to-end asset progression from ideation through first-in-disease designation, integrating scientific rationale, translational endpoints, patient population selection, and regulatory strategy

• Lead or co-lead target and asset evaluation activities including preclinical data package reviews, mechanism-of-action assessments, and translational feasibility analyses

• Provide scientific input to IND-enabling studies, proof-of-concept study designs, and Phase 1/1b protocol development

• Collaborate with the discovery and translational teams to define disease-relevant biomarkers, pharmacodynamic readouts, and patient stratification strategies for early clinical programs

• Actively contribute to R&D programs as a subject matter expert and provide guidance for the clinical development pathway.

• Collaborate with Research Therapeutic Area Lead, RPLs and Immunology core team members to develop and maintain a best-in-class immunology portfolio

Cross-Functional Collaboration & Strategic Input

• Partner with Business Development to assess in-licensing, partnering, and acquisition opportunities within the immunology space, providing scientific due diligence leadership

• Contribute to Target Product Profiles (TPPs), integrated development plans, and portfolio reviews

• Provide disease area expertise to regulatory submissions, clinical study reports, and scientific communications

• Work collaboratively with Medical Affairs, Clinical Operations, and translational colleagues to align development strategies

Qualifications

• MD, DO, or PhD in Immunology, or a closely related discipline

• 12+ years of experience in drug development within a biotech, pharmaceutical, or academic environment

• Demonstrated experience in preclinical to first-in-disease (or equivalent early clinical milestone) in immunology

• Deep scientific expertise in the immunological mechanisms underpinning autoimmune and inflammatory diseases

• Established and active network in drug development with recognized relationships across rheumatology, neuroimmunology, and/or dermatology communities

• Proven track record in evaluating preclinical and clinical assets, including target assessment, d